An observational study in Spinal Muscular Atrophy, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by St. Jude Children's Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Muscular Atrophy, Spinal with a site in United States — 21 open to participants now, 39 under way, 7 of them phase 3. Muscular Atrophy, Spinal · United States.
Among the 121 studies in Muscular Atrophy, Spinal with a site in United States, this one is the 36th largest by planned enrollment of the 43 observational ones that give a count, is one of 8 that started in 2025, is one of 43 observational ones, reaches primary completion later than 13 of the 38 other live ones, and was the 103rd registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →21 of the 121 studies in Muscular Atrophy, Spinal with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
St. Jude Children's Research Hospital · Sites in United States
Biogen · Sites in United States
Ages 0 days–7 mo
Biogen · Sites in United States, Brazil, China and 2 more countries
Ages 15–60
Novartis Pharmaceuticals · Sites in United States
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 5 Years to 20 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 27 · Phase 3 20 · Phase 4 6
First in 1986; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 139 across 114 observational studies indexed under Muscular Atrophy, Spinal.
Median enrollment 33 across the 76 interventional studies, 75 across the 43 observational. Of the 76 that completed or were terminated, 33 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 121 have an industry lead sponsor. The 10 most frequent:
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
St. Jude Children's Research Hospital has 2 studies filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
7 of the studies in Muscular Atrophy, Spinal with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067790Phase 3BiogenA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | 2027-09-24 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT07223320Teachers College, Columbia UniversityHABIT-ILE + FST in Children With SMA | 2026-12-31 |
| NCT07400198Jacqueline MontesGait and Bone Health in SMA | 2027-06-30 |
| NCT06532474St. Jude Children's Research HospitalExploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies | 2027-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 121 studies in Muscular Atrophy, Spinal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.
Primary Objectives
Secondary Objectives
This is an observational study to demonstrate the feasibility of performing MR functional imaging in exercising muscle in patients with SMA. The participants will be prescribed medication by their treating physician, they will not receive any drug as part of this study.
Participants participating in the ML43225 study, will be put into groups depending on their type of SMA and the drugs they may or may not be taking. They will be asked to come to clinic 3 times over one year. Each visit will include magnetic resonance (MR) studies, a muscle ultrasound, a nerve test, muscle function testing, lung function testing, blood work, vital signs, and participants will be asked about their quality of life and daily life activities. After participants have completed the 3 required visits, they will be taken off study.
Those who meet the Eligibility criteria and consent to enrollment on the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SMN-directed therapy inclusion:
Current Evrysdi prescription (Group 1)
Current Spinraza or Zolgensma prescription (Group 2)
Changing from Spinraza or Zolgensma to Evrysdi (Group 3)
Exclusion Criteria:
Current Evrysdi prescription or initiating combination therapy with Evrysdi to current Spinraza or Zolgenzma prescription
Current Spinraza or Zolgensma prescription
Changing from Spinraza or Zolgensma to Evrysdi
Have never received any SMN-directed therapies
Feasibility of performing MR functional imaging in SMA patients
MR functional imaging is considered feasible if ≥ 80% of MRI protocol eligible patients can complete 100% of imaging assessments at baseline and 6 months.
Time frame: At baseline and at 6 months (+/- 14 days)
Reliability of performing MR functional imaging in SMA patients
MR functional imaging is considered reliable if the test-retest reliability is ≥ 0.80 for key imaging biomarkers.
Time frame: At baseline and at 6 months (+/- 14 days)
Compare skeletal muscle oxidative phosphorylation bioenergetics in patients with SMA types 2 and 3 (phosphocreatine)
Real-time 31P MR spectroscopy and CrCEST MRI will be used to measure phosphocreatine within the muscles at rest, during an exercise protocol, and during post-exercise recovery to baseline. Both measure the recovery time in seconds.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Compare skeletal muscle oxidative phosphorylation bioenergetics in patients with SMA types 2 and 3 (creatine concentrations)
Real-time 31P MR spectroscopy and CrCEST MRI will be used to measure creatine concentrations within the muscles at rest, during an exercise protocol, and during post-exercise recovery to baseline. Both measure the recovery time in seconds.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Measure intramuscular fat fraction in major muscle extremity in patients with SMA types 2 and 3
Measurement of thickness of muscle compared to fat on MRI, measured in percentage.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Measure electrophysiological tests of motor neuron function to repetitive nerve stimulation in patients with SMA types 2 and 3
Electrophysiological testing: Compound motor action potential (CMAP, measured in millivolts), motor unit number estimate (MUNE, average 200-400 for most limb muscles), and repetitive stimulation at 3 Hz - right ulnar to abductor digiti minimus and right fibular/peroneal nerve to tibialis anterior muscle. A decrease of more than 40% in the amplitude of CMAP is considered abnormal.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in non-ambulant patients and ambulant patients with SMA types 2 and 3
The Hammersmith Functional Motor Scale Expanded (HFMSE) has a score range from 0-66 with lower scores indicating poorer overall motor function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in non-ambulant patients with SMA types 2 and 3 - Revised Upper Limb Module
The Revised Upper Limb Module (RULM) has a score range 0-37 with lower scores indicating poorer upper limb motor function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in non-ambulant patients with SMA types 2 and 3 - Block and Box Test
The Block and Box Test (BBT) is a measure of gross manual dexterity and is scored by counting the number of blocks carried from one compartment to another. Higher scores are indicative of better manual dexterity.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in ambulant patients with SMA types 2 and 3 - 6-Minute Walk
The 6-Minute Walk (6MW) Test measures how far someone can walk in six minutes, a higher score indicates better exercise tolerance score. A low score correlates with lower function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in ambulant patients with SMA types 2 and 3 - 10 Meter Walk/Run
The 10 Meter Walk/Run (10MW) Test is measured in seconds and assesses walking speed over a short distance. Longer times indicate lower motor function
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in ambulant patients with SMA types 2 and 3 - 4-Stair Climb
The 4-Stair Climb (4SC) Test is measured in seconds and assesses lower extremity power and motor function. Longer times indicate lower motor function
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in ambulant patients with SMA types 2 and 3 - Supine-to-Stand Test
The Supine-to-Stand (STS) Test is measured in seconds and assesses the ability to move from laying on your back to standing up straight. Longer times indicate lower motor function.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Identify changes in motor function in ambulant patients with SMA types 2 and 3 - Timed Up-and-Go Test
The Timed Up-and-Go (TUG) Test is measured in seconds and assesses the ability to stand up from sitting in a chair, walk 10 feet, turn around, walk back, and sit down. Longer times indicate lower motor function
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Assess myometry, or measurement of muscle strength
Myometry measures force in pounds or kilograms and measures the strength of a muscle group. The more force measured indicates more muscle strength.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Muscle ultrasound thickness and echogenicity of 5 muscles - 2 upper limb and 3 lower limb
Muscle thickness is measured in centimeters and echogenicity is measured in gray-scale value. Muscle thickness and echogenicity are related to muscle strength, physical function, muscle mass, and quality of muscle.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Plasma neurofilament light (NF-L) and phosphorylated heavy chain (pNF-H) levels
The NF-L and pNF-H levels are measured in nanograms per milliliter from blood samples and can be an indicator of nerve cell damage. Higher values normally mean more nerve damage is occurring.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Blood SMN protein levels
SMN protein levels are measured in nanograms per milliliter from blood samples. Higher values indicate more SMN protein production which is normally deficit in people with SMA.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Pyruvic acid (mg/dL)
This parameters has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. A normal blood pyruvic acid level is between 0.3 and 1.5 milligrams per deciliter (mg/dL). Elevated pyruvic acid in glycolysis usually indicates a disruption in the normal metabolic pathway.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Lactic Acid (millimoles per liter)
This parameter has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. Normally, blood lactate levels are between 1-2 mmol/L when not exercising. Elevated lactic acid during glycolysis indicates that the body is primarily relying on anaerobic glycolysis, meaning it is breaking down glucose for energy without sufficient oxygen, leading to a buildup of lactate as a byproduct.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Lactate dehydrogenase (LDH) (units per liter (U/L)
This parameters has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. Normal LDH levels in children vary by age. Normal adult range is 140-280 U/L. An elevated level of lactate dehydrogenase (LDH) in glycolysis indicates an increased rate of anaerobic metabolism.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Trough risdiplam drug levels
Trough risdiplam drug level is measured in nanograms per milliliter from blood samples and indicates the concentration of risdiplam in someone's blood stream. Higher values mean someone has more risdiplam exposure. This will only be tested on participants who are taking the drug risdiplam.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Quality of life (QOL) and disability information - Pediatric Quality of Life Inventory (PedsQL)
The Pediatric Quality of Life Inventory (PedsQL) is a 23-item questionnaire measuring health-related quality of life in children and adolescents aged 2-18. Higher scores indicate better quality of life.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
QOL and disability information - Pediatric Outcomes Data Collection Instrument (PODCI)
The Pediatric Outcomes Data Collection Instrument (PODCI) is an 83-86 item questionnaire that measures the health-related quality of life for children and adolescents with musculoskeletal disorders aged 2-18. Higher scores indicate better quality of life.
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
QOL and disability information - SMA Health Index (SMA-HI)
The SMA Health Index (SMA-HI) is a 107 item questionnaire that measures a patient's perception of disease burden in 15 areas of health related to SMA. Higher scores indicate more SMA disease burden
Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)
Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.
Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →